Paper · 42007332
Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis.
Xiao YJ and 7 others. Front Pharmacol, 2025. Cited by 8 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis. Papers, record 42007332. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42007332
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Efficacy and safety of efruxifermin for patients with NASH/MASH: an updated systematic review and meta-analysis.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants0
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
None in this release.
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38,097,670 | A pivotal year for NAFLD and NASH therapeutics. | Nat Rev Endocrinol | 2024 | https://conductscience.org/library/papers/38097670 | PubMed |
| 2 | 40,520,164 | A systematic review and meta-analysis of efruxifermin's efficacy in improving liver fibrosis in patients with NASH/MASH. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40520164 | PubMed |
| 3 | 29,940,269 | Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. | J Hepatol | 2018 | https://conductscience.org/library/papers/29940269 | PubMed |
| 4 | 33,782,057 | The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. | BMJ | 2021 | https://conductscience.org/library/papers/33782057 | PubMed |
| 5 | 37,363,821 | A multisociety Delphi consensus statement on new fatty liver disease nomenclature. | Hepatology | 2023 | https://conductscience.org/library/papers/37363821 | PubMed |
| 6 | 36,976,456 | Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. | J Physiol Biochem | 2023 | https://conductscience.org/library/papers/36976456 | PubMed |
| 7 | 34,536,190 | FGF21 ameliorates hepatic fibrosis by multiple mechanisms. | Mol Biol Rep | 2021 | https://conductscience.org/library/papers/34536190 | PubMed |
| 8 | 40,341,827 | Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. | N Engl J Med | 2025 | https://conductscience.org/library/papers/40341827 | PubMed |
| 9 | 33,381,084 | FGF21: An Emerging Therapeutic Target for Non-Alcoholic Steatohepatitis and Related Metabolic Diseases. | Front Endocrinol (Lausanne) | 2020 | https://conductscience.org/library/papers/33381084 | PubMed |
| 10 | 36,727,674 | AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. | Hepatology | 2023 | https://conductscience.org/library/papers/36727674 | PubMed |
1 to 10 of 39
See all 39 referencesCited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,640,441 | Holding the Line: Navigating Upadacitinib-Induced Neutropenia in Refractory Ulcerative Colitis. | Dig Dis Sci | 2026 | https://conductscience.org/library/papers/42640441 | PubMed |
| 42,213,392 | Polymer-Based and Biomaterial Encapsulation of Probiotics for Improved Viability. | Probiotics Antimicrob Proteins | 2026 | https://conductscience.org/library/papers/42213392 | PubMed |
| 41,874,589 | Exposure to second-generation flame retardants and risk of metabolic diseases: a systematic review and meta-analysis. | Arch Toxicol | 2026 | https://conductscience.org/library/papers/41874589 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42007332
GET https://conductscience.org/api/papers/v1/42007332/references?page=2